Clinical Trial Update: Phase 1 First in Human Study of ZN-d5 as a Single Agent [Phase 1]

View source ↗

Summary

Phase 1 first-in-human trial of ZN-d5 as a single agent has completed, with study conducted in patients with acute myeloid leukemia and non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• ZN-d5

Snippet

Sponsor: K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia, Non Hodgkin Lymphoma | Phase 1 | Status: COMPLETED